Low-density lipoproteins and risk for coronary artery disease

1994, Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II), Circulation, 89, 1329 Stefanick, 1998, Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol, N Engl J Med, 339, 12, 10.1056/NEJM199807023390103 Grundy, 1997, When to start cholesterol-lowering therapy in patients with coronary heart disease, Circulation, 95, 1683, 10.1161/01.CIR.95.6.1683 Gould, 1995, Cholesterol reduction yields clinical benefit, Circulation, 91, 2274, 10.1161/01.CIR.91.8.2274 1984, The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease, JAMA, 251, 351, 10.1001/jama.1984.03340270029025 Buchwald, 1990, Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia, N Engl J Med, 323, 946, 10.1056/NEJM199010043231404 Buchwald, 1998, Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity, Arch Intern Med, 158, 1253, 10.1001/archinte.158.11.1253 Buchwald, 1992, Changes in sequential coronary arteriograms and subsequent coronary events, JAMA, 268, 1429, 10.1001/jama.1992.03490110067031 Azen, 1996, Progression of coronary artery disease predicts clinical coronary events, Circulation, 93, 34, 10.1161/01.CIR.93.1.34 Waters, 1993, Prognostic significance of progression of coronary atherosclerosis, Circulation, 87, 1067, 10.1161/01.CIR.87.4.1067 Davidson, 1997, The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day, Am J Cardiol, 79, 38, 10.1016/S0002-9149(96)00742-4 Bakker-Arkema, 1996, Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia, JAMA, 275, 128, 10.1001/jama.1996.03530260042029 Waters, 1994, Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography, Circulation, 89, 959, 10.1161/01.CIR.89.3.959 Brown, 1990, Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B, N Engl J Med, 323, 1289, 10.1056/NEJM199011083231901 Sacks, 1994, Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients, Lancet, 344, 1182, 10.1016/S0140-6736(94)90506-1 Herd, 1997, Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]), Am J Cardiol, 80, 278, 10.1016/S0002-9149(97)00346-9 1994, Effect of simvastatin on coronary atheroma, Lancet, 344, 633, 10.1016/S0140-6736(94)92082-6 Blankenhorn, 1993, Coronary angiographic changes with lovastatin therapy, Ann Intern Med, 119, 969, 10.7326/0003-4819-119-10-199311150-00002 Pitt, 1995, Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I), J Am Coll Cardiol, 26, 1133, 10.1016/0735-1097(95)00301-0 1997, The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts, N Engl J Med, 336, 153, 10.1056/NEJM199701163360301 Jukema, 1995, Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels, Circulation, 91, 2528, 10.1161/01.CIR.91.10.2528 Brown, 1993, Lipid lowering and plaque regression, Circulation, 87, 1781, 10.1161/01.CIR.87.6.1781 Rossouw, 1995, Lipid-lowering interventions in angiographic trials, Am J Cardiol, 76, 86C, 10.1016/S0002-9149(99)80476-7 Ballantyne, 1997, Effects of lipid lowering therapy on progression of coronary and carotid artery disease, Curr Opin Lipidol, 8, 354, 10.1097/00041433-199712000-00006 Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels, JAMA, 279, 1615, 10.1001/jama.279.20.1615 Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, Lancet, 344, 1383 Tonkin A. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID). Presented at the American Heart Association Scientific Sessions, Orlando, Florida, November 9–12, 1997. Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001 Yusuf, 1996, Cost of prevention, Circulation, 93, 1774, 10.1161/01.CIR.93.10.1774 Grundy, 1998, Statin trials and goals of cholesterol-lowering therapy, Circulation, 97, 1436, 10.1161/01.CIR.97.15.1436 Crouse, 1997, Reductase inhibitor monotherapy and stroke prevention, Arch Intern Med, 157, 1305, 10.1001/archinte.1997.00440330039004 Hebert, 1997, Cholesterol lowering with statin drugs, risk of stroke, and total mortality, JAMA, 278, 313, 10.1001/jama.1997.03550040069040 Bucher, 1998, Effect of HMG-CoA reductase inhibitors on stroke, Ann Intern Med, 128, 89, 10.7326/0003-4819-128-2-199801150-00002 Neaton, 1992, Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease, Arch Intern Med, 152, 56, 10.1001/archinte.1992.00400130082009 Pedersen, 1998, Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S), Circulation, 97, 1453, 10.1161/01.CIR.97.15.1453 Sacks, 1998, Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial, Circulation, 97, 1446, 10.1161/01.CIR.97.15.1446 1998, Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS), Circulation, 97, 1440, 10.1161/01.CIR.97.15.1440 Kannel, 1995, Range of serum cholesterol values in the population developing coronary artery disease, Am J Cardiol, 76, 69C, 10.1016/S0002-9149(99)80474-3 Phillips, 1993, Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events, Circulation, 88, 2762, 10.1161/01.CIR.88.6.2762 Alaupovic, 1997, The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial, Arterioscler Thromb Vasc Biol, 17, 715, 10.1161/01.ATV.17.4.715 Stewart, 1994, Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol, J Am Coll Cardiol, 23, 899, 10.1016/0735-1097(94)90635-1 Miller, 1996, Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project, Circulation, 94, 2146, 10.1161/01.CIR.94.9.2146 Ballantyne CM, Herd JA, Ferlic LL, Dunn JK, Farmer JA, Jones PH, Schein JP, Gotto AM Jr. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation. In press. Manninen, 1992, Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study, Circulation, 85, 37, 10.1161/01.CIR.85.1.37 Jacobson, 1994, Combination therapy with fluvastatin and niacin in hypercholesterolemia, Am J Cardiol, 73, 25D, 10.1016/0002-9149(94)90629-7 Gardner, 1996, Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin, Pharmacotherapy, 16, 419, 10.1002/j.1875-9114.1996.tb02972.x Jacobson, 1994, Fluvastatin with and without niacin for hypercholesterolemia, Am J Cardiol, 74, 149, 10.1016/0002-9149(94)90088-4 Stein, 1996, Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia, J Cardiovasc Pharmacol Ther, 1, 107, 10.1177/107424849600100204 Glueck, 1992, Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias, Am J Cardiol, 70, 1, 10.1016/0002-9149(92)91380-M Wiklund, 1993, Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia, Am J Med, 94, 13, 10.1016/0002-9343(93)90114-5 Brown, 1997, Secondary prevention of heart disease amongst patients with lipid abnormalities, J Intern Med, 241, 283, 10.1046/j.1365-2796.1997.109132000.x Ericsson, 1996, Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients, Lancet, 347, 849, 10.1016/S0140-6736(96)91343-4 Frick, 1997, Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol, Circulation, 96, 2137, 10.1161/01.CIR.96.7.2137 Morgan, 1996, Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia, J Cardiovasc Pharmacol Ther, 1, 195, 10.1177/107424849600100302 Knopp, 1998, Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia, Metabolism, 9, 1097, 10.1016/S0026-0495(98)90284-0 Guyton, 1998, Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia, Am J Cardiol, 82, 737, 10.1016/S0002-9149(98)00448-2 Pearson, 1996, Organization of preventive cardiology service, J Am Coll Cardiol, 27, 1039, 10.1016/0735-1097(96)87736-9 Jacobson TA, Schein JR, Williamson A, Ballantyne CM. Maximizing the cost-effectiveness of lipid-lowering therapy. Arch Intern Med 1998; (In press).